MEDVi Semaglutide Options: Injection, Oral, and Branded Routes

Last reviewed: May 12, 2026 Last updated: September 22, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Director, with a PharmD and MBA specializing in pharmacogenomics and clinical product development. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — evidence-based guidance on GLP-1 therapies and weight-management care. Browse all Peptides & GLP-1 education

Editorial note: PlexusDx publishes this editorial review and offers one of the programs discussed. PlexusDx is not affiliated with MEDVi and has no commercial relationship with the companies named in this article; there are no affiliate links. Information is based on the sources and dates shown.

As of September 22, 2026, MEDVi lists three semaglutide routes: a compounded semaglutide injection taken weekly, a compounded daily oral product shown as "Semaglutide (Capsules)" on one MEDVi page and "GLP-1 Tablets" on another, and branded Wegovy® (pill and injection) through a membership-plus-medication route. The injection is priced at $179 for the first month (new patients) and $299 per refill cycle as displayed; MEDVi's oral tablet runs about $70 a month over its injection rate for the same compound (read on its plan-selection screen), and MEDVi does not publish a tablet total on its public page. These are three different products, not one medicine in three packages, and your prescriber chooses among them.

Which semaglutide formats are offered now?

MEDVi's program page lists compounded semaglutide injection as its lead product, with a daily oral semaglutide product and a branded pathway alongside it. The oral product is named inconsistently across MEDVi's own pages, "Semaglutide (Capsules)" on start.medvi.org and "GLP-1 Tablets" on glp1.medvi.org, so the exact dosage form should be read from the pharmacy label rather than inferred from the marketing name. The branded tile lists Wegovy® pill, Wegovy® injection and Zepbound® injection, with availability "subject to change." MEDVi also lists compounded tirzepatide injection, which is outside this explainer. Source: MEDVi's program page, read September 22, 2026.

Injection and oral products are not automatically equivalent

Sharing an active ingredient does not make two products the same. MEDVi's compounded injection is prepared for an individual prescription by a state-licensed 503A compounding pharmacy; MEDVi names Triad Rx, RedRock Pharmacy and Beaker Pharmacy & Compounding. A compounded oral semaglutide product is likewise a pharmacy preparation. Neither is FDA-approved, and neither is a generic or equivalent version of Wegovy® or Ozempic®. A compounded tablet or capsule is also not the FDA-approved Wegovy® pill, which is a distinct approved product.

Route matters pharmacologically as well. Oral semaglutide is absorbed differently from an injection, and the clinical trials behind the branded injection and the branded pill do not establish outcomes for a compounded injection or a compounded oral formulation. The FDA has published its concerns about unapproved GLP-1 drugs, including compounded products. A licensed pharmacy and a licensed prescriber are safeguards, not FDA approval.

Compounded and branded pathways

MEDVi runs the two pathways on different commercial terms. On compounded plans, MEDVi states that medication is included in the program price, with no membership fee, the same price at every dose, free dietitian visits and care coaching, unlimited 24/7 support and free shipping. On the branded pathway, you pay a monthly membership (listed at $99) plus the medication cost, which is billed separately and quoted at checkout. Prescriptions on either pathway are issued by licensed providers in MEDVi's network after an online intake; MEDVi itself is the telehealth platform, not the prescriber.

The trade-off is straightforward. Branded Wegovy® is an FDA-approved product with a published label and trial record, at a price MEDVi does not publish. The compounded products carry a published all-inclusive price and the regulatory caveats above.

How route affects price and program terms

The table shows what MEDVi displayed for each semaglutide route on September 22, 2026, next to the PlexusDx month-to-month price for the same medication and route. Commercial detail on the injection lives in MEDVi Semaglutide Cost: Injection Prices, Refills, and Plan Terms; the oral product is covered in MEDVi Oral Semaglutide Cost: Tablet Pricing and Plan Comparison.

PlexusDx publishes this comparison and offers one of the programs discussed. Information is based on the sources and dates shown.

Assumptions: MEDVi's billing-cycle length is not published, so refills are shown per cycle; MEDVi's price fields are rendered by script and should be confirmed in its official offer. PlexusDx prices are flat across every dose level and cover the provider visit, prescription, medication and shipping, with no membership fee and no charge until the provider approves the prescription. PlexusDx also offers 3- and 6-month commitment tiers, shown on the product pages with the payment schedule at checkout.

Program terms follow the route too. MEDVi's refund policy applies to both pathways: cancel at least 72 hours before the next billing date, no refund for the cycle in which you cancel, and prescription medication cannot be returned. MEDVi offers 3-, 6- and 12-month bundles; their rates appear in its signup flow and are not published here. If you are weighing MEDVi's oral product against its injection, MEDVi's plan-selection screen shows the tablet at about $70 a month over the injection rate for the same compound, with no tablet total published; ask MEDVi for both figures in writing. A broader look at the oral options is in MEDVi Pills Review: Oral Options, Costs, and What to Verify.

Questions to discuss with your clinician

Route is a clinical decision, and the prescribing clinician makes it. Useful questions to bring to that conversation:

• Which product is being prescribed, exactly: compounded injection, compounded oral, or branded Wegovy®, and why that one for you?
• Which pharmacy will dispense it, and what will the label show for strength and dosage form?
• What is known, and not known, about a compounded oral semaglutide product compared with the approved injection or the approved pill?
• How will follow-up and any dose changes be handled, and does the price change with them?
• What is the cancellation and refund position if the route does not suit you?

Zepbound® is a registered trademark of Eli Lilly and Company; Wegovy® and Ozempic® of Novo Nordisk A/S. PlexusDx is not affiliated with or endorsed by either.

A note on genetics (optional)

PlexusDx offers compounded semaglutide and tirzepatide through its Weight Management Protocols. Separately, and only if it interests you, the GLP-1 & Peptide Pathways Genetic Test ($298) analyzes 14 pathways, 49 peptides, 150+ genetic insights, including variants in FTO, MC4R and TCF7L2 that relate to appetite and glucose-handling pathways. It does not predict how you will respond to any medication and does not tell you which drug, dose or provider is right for you; it is context for a conversation with your clinician. Test before you invest, and treat genetics as a guide, not a guarantee.

This article is educational. PlexusDx is not affiliated with MEDVi and has no commercial relationship with the companies discussed. PlexusDx offers compounded semaglutide and tirzepatide through its own Weight Management Protocols; this article compares approaches in the GLP-1 telehealth space. The GLP-1 & Peptide Pathways Genetic Test analyzes how your genes influence peptide-related biological pathways. It does not predict response to any specific medication and does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol. Compounded semaglutide and tirzepatide are not FDA-approved drug products; they are prepared by state-licensed compounding pharmacies under federal compounding rules and are not the same as Wegovy®, Ozempic®, Zepbound® or Mounjaro®. Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company; Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. PlexusDx is not affiliated with or endorsed by either company.

Frequently Asked Questions

Which semaglutide forms does MEDVi offer?

As of September 22, 2026, MEDVi's pages list a compounded semaglutide injection, a compounded daily oral semaglutide product (named capsules on one page and tablets on another), and branded Wegovy pill and injection through a membership-plus-medication route. Availability of the branded products is described as subject to change, so confirm the current menu in MEDVi's official offer.

Is MEDVi's oral semaglutide the same as the Wegovy pill?

No. MEDVi's oral product is a compounded semaglutide capsule or tablet prepared by a compounding pharmacy. It is not FDA-approved and is not the approved Wegovy pill, which is a distinct product with its own label and trial record. Read the dosage form from the pharmacy label and ask the prescriber what is known about the compounded oral formulation.

How much does each MEDVi semaglutide route cost?

The compounded injection is $179 for the first month for new patients, then $299 per refill cycle as displayed September 22, 2026. MEDVi's oral tablet runs about $70 a month over its injection rate for the same compound (read on its plan-selection screen); MEDVi does not publish a tablet total on its public page. The branded route is a monthly membership plus a separately billed medication cost that is quoted at checkout. Confirm every figure in MEDVi's official offer.

Does the price change if the dose changes at MEDVi?

MEDVi states the same price at every dose on its compounded plans. Its terms add that the final charge may vary with the prescribed medication and the fulfilling pharmacy, so treat the displayed price as a starting point. Dose decisions themselves belong to the prescribing clinician, not to the price list.

Who decides whether I get the injection or the oral product?

The licensed provider in MEDVi's network who reviews your intake decides which product, if any, to prescribe. MEDVi is the telehealth platform, not the prescriber. Bring questions about route, pharmacy, label details and follow-up to that clinician, and ask what is and is not known about a compounded oral semaglutide formulation.

Sources and dates checked

• MEDVi program page (glp1.medvi.org), read September 22, 2026
• MEDVi start page (start.medvi.org), read September 22, 2026
• MEDVi cancellation and refund policy, read September 22, 2026
• PlexusDx Semaglutide Injection product page, verified September 22, 2026
• PlexusDx Semaglutide Oral product page, verified September 22, 2026
• FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. Sources and the dates they were checked are listed at the end of the article.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services, and offers compounded GLP-1 programs through its Weight Management Protocols. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.